Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: IntegenX Names Schueren as CEO; Applied BioCode Hires Aye as VP

Premium

IntegenX this week announced the appointment of Robert Schueren as CEO.

Schueren most recently served as vice president and general manager of genomics for Agilent Technologies. Prior to joining Agilent in 2010, he was the global head of clinical biomarkers and operations and deputy global head of molecular medicine labs at Genentech. Schueren also served as senior director of development sciences and director of companion diagnostics at Genentech. Schueren has also served as executive vice president and COO of Arcturus Bioscience; and has worked for Accumetrics, Biosite Diagnostics, and Gen-Probe (now Hologic).

Stevan Jovanovich, a founder and past president and CEO of IntegenX, will remain with the company as chief technology officer.


Applied BioCode said this week that it has appointed Michael Aye as vice president of molecular products.

Aye has previously been employed by Focus Diagnostics and Beckman Coulter. Prior to his industrial experience, he spent 10 years in academia focused on research in molecular genetics and microbiology.

Aye obtained a BS in microbiology in 1995 from California State University, Long Beach, and PhD in biology (molecular genetics) in 2001 from the University of California, Irvine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.